Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06622005
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-30
Brief Title:
SX-682 in Combination With Carfilzomib Daratumumab-Hyaluronidase and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Phase 1 Trial of SX-682 a CXCR 12 Inhibitor in Combination With Standard of Care Treatment in Patients With Relapsed or Refractory Multiple Myeloma RRMM
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase I trial tests the safety and side effects of SX-682 in combination with standard of care treatment carfilzomib daratumumab-hyaluronidase and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement relapsed or that has not responded to previous treatment refractory SX-682 works by blocking certain sites on cells that suppress the ability of the immune system to destroy tumor cells Blocking those specific sites allows other cells of the immune system to become free to kill tumor cells Carfilzomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth Daratumumab is in a class of medications called monoclonal antibodies It binds to a protein called CD38 which is found on some types of immune cells and tumor cells including myeloma cells Daratumumab may block CD38 and help the immune system kill tumor cells while hyaluronidase helps to deliver daratumumab to CD38-expressing tumor cells through a subcutaneous injection Dexamethasone is in a class of medications called corticosteroids It is known to kill myeloma cells and is also used to reduce inflammation and lower the bodys immune response to monoclonal antibodies like dratumumab and help lessen its side effects Giving SX-682 in combination with carfilzomib daratumumab-hyaluronidase and dexamethasone may be safe and tolerable in treating patients with relapsed or refractory multiple myeloma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None